马上注册，结交更多好友，享用更多功能，让你轻松玩转社区
您需要 登录 才可以下载或查看，没有帐号？立即注册 
x
辉瑞正式向DA提交乳腺癌新药Palbociclib新药申请 发布日期：2014-08-19 来源：onclive
美国辉瑞 8月18日 宣布，公司已经向美国食品药品监督管理局（FDA）正式提交Palbociclib的新药申请（NDA），新药申请审核为60天。
此次辉瑞提交的是Palbociclib联合来曲唑(Letrozole)用药，其适应症为雌激素受体阳性、HER2阴性的晚期乳腺癌。申请提交是基于公司临床II期研究。 Palbociclib是一种新型口服CDKs-4和CDKs-6抑制剂，通过重新获得细胞周期把控，起到阻止癌细胞扩散的作用。该药物于2013年4月被美国FDA授予“突破性疗法”认证。该药物已经进入2项临床III期试验。
Pfizer Seeks FDA Approval for Palbociclib
Pfizer has submitted a New Drug Application for palbociclib plus letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer, based on findings from the phase II PALOMA-1 trial.
The FDA will review the application within 60 days, at which point the agency will establish a review timeline for the novel CDK 4/6 inhibitor under the Prescription Drug User Fee Act. The fastest review under this program provides a decision within 6 months.
“Today’s submission marks an important milestone for Pfizer and palbociclib, and a potential advance for women with advanced breast cancer,” Garry Nicholson, president of Pfizer Oncology, said in a press release.
Inhibition of CDK 4/6 prevents DNA replication by prohibiting progression from G1 to S phase during cell division. Blocking this mechanism prevents tumor cell proliferation through control of the cell cycle. The rationale for the combination of an aromatase inhibitor with palbociclib stemmed from early preclinical evidence suggesting that CDK 4/6 is more active in patients with ER-positive breast cancer, as a result of an intact retinoblastoma (Rb)-pathway.
Palbociclib initially generated excitement at the 2012 San Antonio Breast Cancer Symposium when interim results from the PALOMA-1 trial demonstrated a dramatic improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole versus letrozole alone. based on these findings, the FDA granted palbociclib a breakthrough therapy designation in April 2013.
In the open-label PALOMA-1 study, 165 postmenopausal patients with ER-positive, HER2-negative advanced breast cancer were randomized in a 1:1 ratio in two parts: Part 1 contained 66 patients and Part 2 had 99 patients. Continuous daily letrozole was administered at 2.5 mg with or without palbociclib at 125 mg daily for 3 weeks followed by 1 week of rest until progression. The primary endpoint was PFS by investigator assessment.
According to an updat presented at the 2014 AACR Annual Meeting in April 2014, the median PFS was 20.2 months with palbociclib compared with 10.2 months for letrozole alone (HR = 0.488; P = .0004). The median overall survival (OS) was 37.5 months with palbociclib compared with 33.3 months with letrozole alone (HR = 0.813; 95% CI, 0.492-1.345; P = .2105). However, this first analysis of OS contained data from only 61 patient (37%) and was not deemed statistically significant.
The most commonly reported treatment-related adverse events in the combination arm were neutropenia, leukopenia, anemia, and fatigue. Neutropenia in the study was not cumulative and febrile neutropenia was not reported.
According to analysis presented at the 2014 ASCO Annual Meeting, palbociclib-induced neutropenia is generally short lasting and reversible with conservative management. This study combined safety data from 140 patients across two phase II studies of single-agent palbociclib in patients with various Rb-positive tumors. Overall, grade 3/4 neutropenia was present in 39% of patients. Grade 3 anemia occurred in 4% of patients and grade 3 thrombocytopenia was apparent in 9%.
A number of Pfizer-sponsored phase III clinical trials are exploring palbociclib as a treatment for patients with advanced breast cancer. Given the benefit demonstrated in the PALOMA-1 trial, these studies will be randomized in a 2:1 ratio favoring treatment with palbociclib
The PALOMA-2 trial is comparing the combination of palbociclib and letrozole with letrozole alone as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer (NCT01740427). The PALOMA-3 trial is comparing palbociclib plus fulvestrant against fulvestrant alone in women with HR-positive, HER2-negative metastatic breast cancer following progression on prior endocrine therapy (NCT01942135).
In addition to Pfizer sponsored studies, a number of investigator-led phase III trials have been established to explore palbociclib across a number of settings. These studies randomize patients in a 1:1 ratio to palbociclib in combination with hormonal therapy or chemotherapy.
The open-label phase III PEARL trial will compare exemestane plus palbociclib with capecitabine in HR-positive patients with metastatic breast cancer who are resistant to treatment with non-steroidal aromatase inhibitors (NCT02028507). The phase III PENELOPE-B trial will examine post-neoadjuvant treatment with palbociclib plus endocrine therapy in HR-positive patients with residual disease following chemotherapy and surgery (NCT01864746).
| 
|手机版|药群论坛
( 蜀ICP备15007902号 )
收藏
支持
反对